The Continuous Glucose Monitoring Devices Market, estimated at USD 7.81 Bn in 2025, is expected to exhibit a CAGR of 9.9% and reach USD 15.12 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Sensors segment held dominant position in the global continuous glucose monitoring devices market in 2023, accounting for 39.3% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
Increasing awareness among people about diabetes care and the benefits of CGM is one of the key trends expected to boost the growth of the global continuous glucose monitoring devices market. Growing awareness among people about the benefits of CGM device, such as minimally invasive, speedy and accurate results, and pain free, among others. This in turn leads to increasing demand for these devices. According to the American Diabetes Association, around 133 million Americans live with diabetes or prediabetes. More than 10 million Americans (or 31%) are treated with insulin and stand to benefit from a continuous glucose monitors. This trend is expected to continue during the forecast period, driving the market growth.
Competitive Landscape:
Major players operating in the global continuous glucose monitoring devices market are Abbott, Medtronic, Dexcom, Inc., Novo Nordisk A/S, Ypsomed, GlySens Incorporated, and F. Hoffmann-La Roche Ltd., among others.
Recent Developments:
In May 2023, January AI launched a new AI-enabled app to estimate and predict glucose response of people to more than 32 million food items. The tool requires users to wear a continuous glucose monitor (CGM) only once and it can function even if members are not using a CGM.
In February 2022, the Food and Drug Administration (FDA) approved Senseonics’ new continuous glucose monitor (CGM), called the Eversense E3 System, for diabetes with a sensor that can last for up to 6 months. According to the company, the device is the longest lasting CGM approved in the United States and the world.
Contact Us